Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Berinert is a plasma-derived C1 esterase inhibitor used to treat acute abdominal, facial, or laryngeal attacks of hereditary angioedema in adults and children. It replaces deficient or dysfunctional C1 inhibitor activity. Berinert is supplied as a freeze-dried powder that is mixed with sterile water before intravenous injection.
read more about berinert ...C1 esterase inhibitor is a normal plasma protein that regulates several enzyme cascade systems, including complement and contact pathways. In hereditary angioedema, deficient or dysfunctional C1 inhibitor permits excessive generation of mediators linked to swelling. Berinert raises functional C1 inhibitor activity and restores regulation of these pathways during an acute attack.
Berinert is approved for acute abdominal, facial, or laryngeal hereditary angioedema attacks in adult and pediatric patients. Its prescribing information does not establish prophylactic use. Laryngeal attacks can obstruct the airway, so patients who self-administer Berinert for throat swelling are instructed to seek immediate medical care after treatment.
The labeled dose is 20 International Units per kg of body weight by intravenous injection. The freeze-dried powder is reconstituted with the supplied sterile water before use. Patients or caregivers can self-administer after proper training. Doses lower than 20 International Units per kg are not recommended under the prescribing information.
Berinert can cause severe hypersensitivity reactions, including hives, chest tightness, wheezing, low blood pressure, and anaphylaxis. Arterial and venous thromboembolic events have also been reported with C1 esterase inhibitor products. Since Berinert is made from human plasma, infectious agent transmission remains a theoretical risk despite manufacturing steps that reduce that risk.
Berinert treats acute abdominal, facial, or laryngeal hereditary angioedema attacks in adults and children.
Berinert is given by intravenous injection after the freeze-dried powder is mixed with the supplied sterile water.
The labeled dose is 20 International Units per kg of body weight for an acute hereditary angioedema attack.
No. Its prescribing information does not establish prophylactic therapy.
BERINERT (C1 Esterase Inhibitor [Human]) Prescribing Information. https://labeling.cslbehring.com/pi/us/berinert/en/berinert-prescribing-information.pdf. Date Accessed September 16, 2026.
BERINERT. CSL Behring Medical Affairs. https://medicalaffairs.cslbehring.com/products/allergy-and-immunology/berinert. Date Accessed September 16, 2026.
C1-Esterase Inhibitor Human Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a622016.html. Date Accessed September 16, 2026.
DailyMed - BERINERT (human C1-esterase inhibitor). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ea0c7fe-da9d-4218-a080-0509e09bedc6. Date Accessed September 16, 2026.
Search Orphan Drug Designations and Approvals - C1 Esterase Inhibitor (Human). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=67592. Date Accessed September 16, 2026.